WO2000000192A9 - INHIBITION OF NF-λB MEDIATED TISSUE INJURY USING DITHIOCARBAMATE DERIVATIVES - Google Patents
INHIBITION OF NF-λB MEDIATED TISSUE INJURY USING DITHIOCARBAMATE DERIVATIVESInfo
- Publication number
- WO2000000192A9 WO2000000192A9 PCT/US1999/014490 US9914490W WO0000192A9 WO 2000000192 A9 WO2000000192 A9 WO 2000000192A9 US 9914490 W US9914490 W US 9914490W WO 0000192 A9 WO0000192 A9 WO 0000192A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cyclic
- dtc
- patient
- group
- derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
Definitions
- endothelial-derived biologically active agents in the form of either surface proteins or locally secreted soluble factors, that exert opposing effects to either increase or decrease the degree of vasoconstriction, promote or prevent coagulation, enhance or impede platelet and leukocyte adhesion Verrier et al . , Ann. Thorac. Sur ⁇ . 62(3): 915-22, 1996.
- these dynamic endothelial cell functions work in concert to promote blood flow.
- endothelial cells undergo phenotypic changes that allow them to participate actively in the inflammatory response. This response, termed endothelial cell activation, enhances vasoconstriction, coagulation and leukocyte adhesion. Pober et al . , Transplantation
- vasomotor, procoagulant and proinflammatory changes likely exist as protective mechanisms, when the stimuli are severe as in the case of cardiovascular disease, shock and sepsis, or chronic, as occurs with atherosclerosis or aging, the response may become excessive resulting in damaged tissue and impaired organ function.
- Proposed inhibitory agents include monoclonal antibodies and small molecule inhibitors to prevent neutrophil-endothelial cell interactions, inhibitors of oxygen derived free radicals and protease inhibitors to prevent neutrophil mediated injury after neutrophils become adherent, and inhibitors of neutrophil chemotaxis which target such molecules as C5a, PAF, or LTB4.
- Transcriptional regulation of inflammatory genes activated by oxidative stress provides a potential focal point for controlling endothelial cell activation.
- signal transduction pathways including the various protein kinase cascades, thought to be involved in entothelial activation.
- Quiescent endothelial cells lining the microvasculature respond to injury by activating signal transduction pathways that transmit signals through the cytoplasm to the nucleus . These signals result in the transcription, translation, and expression of proinflammatory, procoagulant , and vasoactive genes that characterize endothelial cell activation.
- Additional "downstream" events involved in endothelial cell activation include microthrombosis from tissue factor expression, neutrophil adhesion secondary to expression of leukocyte adhesion molecules (eg., E-selectin, VCAM-1, ICAM-1, P-selectin) , and the release of cytokines, chemokines and growth factors (IL-1, IL-6, IL-8, b-IFN, MCP-1, TNF, GM-CSF, M-CSF, G-CSF) that contribute to local cellular activation and chemotaxis.
- leukocyte adhesion molecules eg., E-selectin, VCAM-1, ICAM-1, P-selectin
- cytokines, chemokines and growth factors IL-1, IL-6, IL-8, b-IFN, MCP-1, TNF, GM-CSF, M-CSF, G-CSF
- NF- ⁇ B nuclear factor-kappa-B
- Baeuerle et al . Ann. Rev. Immunol. 12:141-79 , 1994; Collins T, et al., Faseb. J. 9 (10) .-899-909, 1995; Parry et al . , Arterioscler. Thromb. Vase. Bio. 15:612-621, 1995.
- NF-zB is composed of similar subunits as are found in other members of the "NF- ⁇ B/Rel family" of transcription factors.
- DNA-binding proteins in this family p50, p52, p65 (also known as RelA) , c-Rel, and RelB, are known to be involved in mammalian transcriptional regulation.
- Members of this family are defined by the presence of a highly conserved region of approximately 300 amino acids called the "rel homology domain", which bears the DNA binding site.
- a consensus DNA binding sequence is present, and the carboxy-terminus of the rel homology domain in all family members contains a highly specific cluster of positively charged amino acids that function as nuclear localization signals.
- the p65 subunit in association with p50 or c-Rel (both present in NF- ⁇ B) , is the most common heterodimer, subserving the trancriptional activation of many genes involved in immunologic and inflammatory responses. Parry et al . , J. Bio. Chem. 269:20823-20825. 1994.
- NF-KB is thought to regulate transcription of many genes involved in endothelial activation and is itself activated by diverse stimuli (see, eg., Baeuerle et al . , Ann. Rev. Immunol. 12:141-79. 1994), this transciptional regulatory factor represents a potential target for blocking a range of inflammatory processes. Furthermore, because NF-.B also plays a regulatory role in oncogenesis and in replication of the human immunodeficiency virus (HIV) , pharmacologic targeting of NF-KB will likely yield beneficial treatments for these disease states as well.
- HIV human immunodeficiency virus
- NF- ⁇ B activity in vivo has been proposed based on a gene therapy directed approach.
- gene therapy is commonly used to insert genes into patients with inherited gene defects, the concept of gene therapy is rapidly being broadened to include transient gene therapy to prevent and treat inflammatory responses .
- investigators have proposed a number of gene therapy techniques to inhibit NF-/.B. These include anti-sense oligonucleotides directed at p65.
- gene therapy for a majority of inflammatory disorders attributable to endothelial cell activation is not currently practical, because methods to deliver genes and achieve high transduction or transfection efficiency are extremely limited.
- a pharmacologic approach to inhibit NF- ⁇ B would have significant advantages over gene therapy oriented therapies.
- a pharmacologic approach would likely be easier and safer than inserting foreign DNA into patients using viral or lipid based vectors, both of which may yield an inflammatory response by themselves.
- a successful pharmacologic agent might be amenable to repeated use to allow chronic treatment, in contrast with monoclonal antibody or gene directed approaches.
- NF-/.B can be inhibited by a number of drugs in vi tro
- a pharmacologic agent that is non-toxic and effective for inhibiting inflammation has not heretofore been available for use in whole animal models.
- dithiocarboxylates which include dithocarbamates (DTCs) and thiuramsulfides (TSs) .
- DTCs dithocarbamates
- TSs thiuramsulfides
- PTDS disulfiram
- DDT diethyldithiocarbamate
- PDTC pyrrolidinedithiocarbamate
- DDT has been shown to protect against hepatotoxic agents and to exert anticarcinogenic activity.
- DDT has been used as an antitoxic agent to ameliorate the side effects of some chemotherapeutic agents.
- DDT has been of interest, not only for inducing intolerance of alcohol by increase of acetaldehyde , but also in the treatment of hereditary copper thesaurismosis (Wilson's disease) and as an antidote against nickel carbonyl intoxication.
- Intravenous DDT has also been investigated for potential therapeutic use against HIV-related disease.
- PDTC has been reported by some researchers to be an effective inhibitor of NF- ⁇ B in vi tro .
- the rabbit model is widely accepted as a model system that is well correlated with human inflammatory intervention
- the rat is far from an ideal study organism for this purpose.
- Many of the hemodynamic changes associated with the systemic inflammatory response syndrome and other dysregulated inflammatory responses in humans are observed in rabbits, but the same is not true in rats.
- Rats require exorbitantly large doses of endotoxins or cytokines to produce correlative inflammatory responses. This suggests that fundamental interspecies differences exist between the immune system of rats compared to that of humans, which precludes drawing satisfactory correlations to humans from observations in rats.
- the rabbit on the other hand is well suited for studying responses to inflammatory mediators such as LPS, IL-1 and for evaluating inhibitory agents of inflammatory pathways and mechanisms.
- the rabbit and humans have similar dose responses to intravenously injected cytokines under both normal and experimental (eg., anesthetic) conditions.
- cytokines under both normal and experimental (eg., anesthetic) conditions.
- the reported effects may have been the result of an ionotropic or chronotropic effects on the heart, as opposed to an indirect effect on the peripheral vasculature as Liu's group proposed. It is therefore quite possible that PDTC facilitated changes in blood pressure independently of gene activation.
- DDT dithiocarbamates
- toxic side effects have been attributed to many representative compounds. These side effects include neurogenic effects and gastrointestinal ulcers.
- DDT is neurotoxic, in part, due to its reactivity with sulfhydryl groups, which impairs the antioxidant activity of glutathione and the DDT-inhibited detoxification of cytotoxic products of peroxidized lipids.
- An important function in the DDTC-induced neurotoxcicity is likely its ability to enhance preferentially the redistribution of endogenous copper to the brain, which can yield toxic side effects. Cytosolic and mitochondrial aldehyde dehydrongenase may also be involved in toxic side effects of certain DTCs.
- ProDTC, and SDTC remain unexplained. These differences cannot be entirely explained by the added carboxy group in ProDTC and SDTC, because SDTC behaved comparably to DDT. It is possible that these differences to other characteristics of the compounds, for example the unique ring structure of ProDTC. A different redox potential may result from the different structures, which could be responsible for a different rate of oxidation to either TDS or to mixed disulfides. However, further studies are required to pinpoint the structural and functional attributes that mediate toxic effects, stability characteristics, clearance and other pharmacokinetic behaviors of DTCs and their derivatives.
- ancillary objects of the invention are to provide antiinflammatory methods which do not elicit adverse responses, such as adverse cytokine and cellular immune responses and secondary inflammatory responses, and which are permissive of chronic treatments.
- Yet another object of the invention is to achieve a pharmacologic antiinflammatory treatment that employs highly efficacious and minimally toxic agents to optimize treatment and reduce patient morbidity.
- the invention aspires to target primary inflammatory mechanisms and pathways.
- the invention seeks to resolve outstanding difficulties in disabling NF-/-B-mediated inflammatory pathways, and in curtailing global impacts of oxidative stress-induced inflammatory responses.
- a more challenging of objective of the invention is achieve focal inhibition of inflammatory pathways while avoiding disablement of beneficial inflammatory mechanisms, such as sustained cytokine function and immune competence that correlate with patient recovery.
- the invention fulfills these objects and satisfies other objects and advantages by providing methods for treating inflammatory responses in a mammalian patient based on administration of cyclic dithiocarboxylate (DTC and TS) derivatives.
- Preferred methods within the invention involve administering an antiinflammatory effective amount of a cyclic DTC or TS derivative to a mammalian patient to yield a detectable or substantial antiinflammatory response (ameliorative or preventative) in the patient.
- Cyclic DTC or TS derivatives for use within the invention exhibit antiinflammatory activity against a wide range of inflammatory conditions and disease states. These compounds comprise a discrete family of DTC and TS derivatives, and are preferably synthesized using a cyclic, secondary amine. Cyclic DTCs for use within the invention preferably share the general formula R1,R2-N-C (S) S-R3 , wherein Rl and R2 constitute a cycle including the nitrogen atom of the dithiocarbamate .
- Preferred TS derivatives share the general formula R1,R2-N-C(S) -Sx-C(S) -N-R3,R4, wherein x is 1 to 8, and wherein Rl, R2 and R3 , R4 constitute independently a cycle including the nitrogen atoms of the respective dithiocarbamate residue.
- Alternative embodiments of the invention employ a cyclic, substituted DTC or TS derivative, or a DTC or TS derivative having one or more structural modifications selected from substituent (s) in a bridge portion of a ring member of the compound, heteroatom(s) within the bridge portion, carbonyl function (s), and/or dehydrogenation to yield one or two double bonds within the compound.
- a further desired property of useful, cyclic DTC or TS derivatives within the invention is increased hydrophilicity as compared to that of a parent compound lacking the foregoing substituent (s) , heteroatom(s) , carbonyl function (s), and/or dehydrogenation.
- Figures 1A and IB depict examples of cyclic, secondary amine precursors for synthesis of cyclic derivatives of DTCs and TSs for use within the invention are provided in Figures 1A and IB.
- Figure 2 depicts examples of preferred substituents that may be with a cyclic, secondary amines to yield preferred, cyclic, substituted secondary amine precursors for synthesis of DTC and TS derivatives useful within the invention.
- Figures 3 and 4 depict examples of cyclic, substituted secondary amines for synthesis of preferred DTC and TS derivatives for use within the invention.
- Figure 5 depicts an exemplary synthetic reaction of CS 2 and L-proline in ethanol and NH 3 to yield a salt of a preferred DTC derivative, prolinedithiocarbamate (ProDTC) for use within the invention.
- ProDTC prolinedithiocarbamate
- Figure 6 illustrates additional examples of reactions yielding preferred DTC derivatives for use within the methods of the invention.
- Figures 7 and 8 depict hemodynamic parameters from rabbits treated with PBS + saline (closed squares) , PBS + LPS (open diamonds) , or PDTC + LPS (open circles) .
- Figure 7 depicts Mean arterial pressure (MAP; mm Hg)
- Figure 8 depicts Heart Rate (HR; beats/min) .
- Data are presented as the mean for six rabbits in each group. The (*) symbol indicates values significantly different when compared to time 0 (P ⁇ 0.05 by paired t-test) .
- Figures 9-12 depict hemodynamic parameters from rabbits in Group 1 (PBS + saline; open squares) , Group 2 (PBS + IL-la; closed squares) , Group 3 (PDTC + IL-la; open circles) , and Group 4 (ProDTC + IL-la; closed circles) .
- Percent change of the value at t 0 min for Mean arterial blood pressure (MAP) ( Figure 9) ; Systemic vascular resistance (SVR) ( Figure 10) ; Cardiac output (CO) ( Figure 11) and heart rate (HR) ( Figure 12) .
- MAP Mean arterial blood pressure
- SVR Systemic vascular resistance
- CO Cardiac output
- HR heart rate
- panel A represents HUVECs exposed to TNF- c. (lOOU/ml) for a designated time period.
- the top panel is a Western blot using anti-I-B ⁇ antibody of HUVEC cytoplasmic extracts.
- the bottom panel is an electrophoretic mobility gel shift assay (EMSA) utilizing a P 32 radiolabled oligo containing the NF-KB consensus sequence.
- ESA electrophoretic mobility gel shift assay
- top panel is a Western blot with an anti-1.Bo. antibody and the bottom panel is an EMSA with the NF-/.B consensus oligo.
- panel A represents HUVECs exposed to H 2 0 2 (500 ⁇ M) for a designated time course.
- Panel B represents HUVECs exposed to pervanadate (PV) (lOO ⁇ M) for a designated time course.
- the top panel in each are Western blot using an anti-I «Bc. antibody and the bottom panels are EMSA' s with the NF-KB consensus oligo.
- panel A provide a representative EMSA of nuclear proteins isolated from HUVECs exposed to TNF-o. (100 U/ml) for 180 minutes with or without 60 minutes of pretreatment with various concentrations of ProDTC.
- the lanes are 1 to 6 from left to right.
- Lane 1 represents control cells that were exposed to saline only.
- Lane 2 represents the positive control cells that were exposed to TNF in the absence of ProDTC.
- Lanes 3-5 represent cells pretreated with 100, 200, or 500 ⁇ M of ProDTC respectively.
- Lane 6 is a cold competition assay of nuclear proteins incubated with cold probe prior to the addition of radiolabeled probe and successful elimination of the band demonstrates the NF-.B specificity.
- panel B is a representative EMSA of nuclear proteins isolated from HUVECs exposed to pervanadate (PV) (200 ⁇ M) for 120 minutes with or without 60 minutes of pretreatment with various concentrations of ProDTC.
- the lanes are 1 to 6 from left to right.
- Lane 1 represents the control cells that were exposed to saline only.
- Lane 2 represents the positive control cells that were exposed to PV in the absence of ProDTC.
- Lanes 3-5 represent cells pretreated with 100, 200, or 500 uM of ProDTC respectively.
- Lane 6 is a cold competition assay of nuclear proteins incubated with cold probe prior to the addition of radiolabeled probe and successful elimination of the band demonstrates the NF- ⁇ B specificity.
- FIG. 22 illustrates the comparative effects of PDTC and Pro-DTC on regional myocardial ischemia in an ischemia-reperfusion model. These data show that ProDTC administration results in a significantly greater reduction in myocardial infarct size in comparison to PDTC.
- the invention described herein provides methods for treating a diverse array of inflammatory responses, conditions, and disease states in a mammalian patient.
- the methods of the invention involve administering an antiinflammatory effective amount of a cyclic dithiocarbamate (DTC) or thiuramsulfide (TS) derivative .
- DTC cyclic dithiocarbamate
- TS thiuramsulfide
- Preferred methods within the invention involve administering an antiinflammatory effective amount of a cyclic DTC or TS derivative to specifically inhibit NF-KB activity and/or oxidative stress while not substantially inhibiting other pathways involved in inflammation.
- the methods of the invention leave intact the patient's ability to fight infection.
- Cyclic DTC or TS derivatives that are useful within the invention exhibit antiinflammatory activity.
- antiinflammatory activity means that the compound detectably or substantially inhibits one or more targeted inflammatory responses. These responses are measured by standard, in vi tro or in vivo, assays, eg., cellular toxicity assays, pathology assays, immunohistochemical assays, cytokine assays, physiological assays (eg., blood pH, arterial pressure, and heart rate) , and the like, which assays are generally known in the art.
- Useful assays for determining antiinflammatory activity, for determining an "antiinflammatory effective amount" of compounds for use within the methods of the invention, and for evaluating the efficacy of methods disclosed herein include, but are not limited to, all of the assays incorporated in the examples below, as well as all assays set forth in the references cited herein (all of which are incorporated herein by reference in their entirety for all purposes to the same extent as if each of said references were incorporated individually in local and specific context) or otherwise known in the art .
- Inflammatory responses which can be measured for determining antiinflammatory activity, for determining an antiinflammatory effective amounts of compounds, and for evaluating the efficacy of methods of the invention include, but are not limited to, all measurable parameters indicative of the level of risk or the extent of inflammatory activity or related injury associated with: ischemia-reperfusion injury, complications of cardiopulmonary bypass or extracorporeal membrane oxygenation (ECMO) , systemic inflammatory induced shock syndrome (eg., associated with CPB, ECMO, shock, sepsis, or pancreatitis) , intimal hyperplasia, atherosclerosis, arthritis, chronic inflammatory autoimmune disease, inflammatory skin disease, periodontal disease, inflammatory pulmonary injury (eg., associated with ARDS, Asthma, COPD) , gastrointestinal inflammatory disorders, and adverse sequelae associated with surgical procedures or injury, among other inflammatory conditions and disease states.
- ischemia-reperfusion injury complications of cardiopulmonary bypass or extracorporeal membrane oxygenation (ECMO)
- Antiinflammatory effective compounds, and antiinflammatory effective amounts of compounds for determining dosages within the methods of the invention are capable of yielding, or yield, an antiinflammatory response as defined above which is detectable compared to an accepted control value or response.
- an ischemia/reperfusion assay an IL-1-induced inflammation or shock assay, or a cytokine assay (as described in the examples below)
- the compound (or antiinflammatory effective amount thereof) will yield a detectable antiinflammatory response as compared to a relevant control value (eg., the value of a parameter measured in an untreated sample, or a baseline physiological measurement) .
- a relevant control value eg., the value of a parameter measured in an untreated sample, or a baseline physiological measurement
- compounds that exhibit antiinflammatory activity are defined as yielding a "substantial" antiinflammatory response.
- a substantial response will vary at least 10% (above or below depending upon the parameter being measured) from the relevant control value. More preferably, the antiinflammatory response will vary 10- 20%, sometimes 20-50%, and most preferably 50-100%, 100-200%, or more, compared to the relevant control value.
- Antiinflammatory effective compounds within the invention comprise a discrete group of structurally and functionally related DTC and TS derivatives. These derivatives are preferably synthesized using a cyclic, secondary amine.
- Cyclic DTCs for use within the invention preferably share the general formula R1,R2-N-C (S) S-R3 , wherein Rl and R2 constitute a cycle including the nitrogen atom of the dithiocarbamate.
- Preferred TS derivatives share the general formula R1,R2-N-C(S) -Sx-C(S) -N-R3,R4, wherein x is 1 to 8, and wherein Rl, R2 and R3 , R4 constitute independently a cycle including the nitrogen atoms of the respective dithiocarbamate residue.
- Operative DTC and TS derivatives within the invention may have 5- to 7-membered ring structure (s) , with 4- to 6-membered bridge component (s) .
- the ring may contain either zero, one, or two double bonds.
- Preferred members of each group bear one or more, and preferably one or two substitutents in the bridge portion(s), eg., R4,R5 or R5, R6.
- the substituents may be selected from carboxyl, carboxylester, hydroxyl, nitro, amino or mercapto substitutents.
- DTC and TS derivatives for use within the invention are characterized by having, alternatively or in addition to the above noted substituent (s) , one or more heteroatoms (S, N, or O) within the bridge portion (s) .
- Additional preferred derivatives may feature, alternatively or in combination with the above noted substituent (s) and/or heteroatom(s) , one or two carbonyl functions.
- Still other preferred derivatives feature, alternatively or in combination with the above noted substituent (s) and/or heteroatom(s) and/or carbonyl function (s), dehydrogenation to yield one or two double bonds.
- Characteristic of preferred DTC and TS derivatives for use within the invention is that they exhibit pharmacological properties unique to cyclic compounds and are more hydrophilic as compared to hydrophilicity of a parent compound lacking the above noted substituent (s) and/or heteroatom(s) and/or carbonyl functiono (s) and/or dehydrogenation features.
- Exemplary DTC and TS derivatives exhibiting the aforementioned structural and functional characteristics to yield therapeutic agents for use within the methods of the invention include prolinedithiocarbamate (ProDTC) , thioproline-dithiocarbamate (TProDTC) , prolinethiuramidisulfide (ProTDS) , and thioprolinethiuramidisulfide (TProTDS) .
- ProDTC prolinedithiocarbamate
- TProDTC thioproline-dithiocarbamate
- ProTDS prolinethiuramidisulfide
- TProTDS thioprolinethiuramidisulfide
- the cyclic DTC or TS derivative is administered in a dosage of between about 0.5 and 500 mg/kg body weight.
- the dosage is between about 10 mg/kg and 100 mg/kg, and more preferably between about 20 mg/kg and 50 mg/kg.
- the administration schedule can range from a continuous infusion, to once every other day, to 6 or more administrations a day, with dose levels and administration protocols being selected by the health professional.
- treatments according to the invention can be in the form of a one time dose, as in the case of a trauma patient in shock or heart surgery patient.
- short term, long term, or continuous treatments may be selected.
- long term treatments can be employed to prevent chronic oxidative stress induced injury, to treat advanced lesions, or to manage high-risk patients.
- Long term treatments can extend for years with dosages ranging from 0.5 to 500 mg/kg body weight administered at intervals ranging from once every other day to three times daily.
- the active compounds can also be administered in a period that is concurrent with or closely preceding a surgical procedure or other event anticipated to produce a risk of inflammatory injury, for example prior to coronary bypass.
- methods are provided which involve administration of a cyclic DTC or TS derivative concurrent with, or within an antiinflammatory effective period preceding, a surgical procedure, whereby the administration reduces or eliminates risk of abnormal inflammatory responses normally associated with the procedure.
- a cyclic DTC or TS derivative, or a mixture of these and/or other compounds can be administered by a variety of routes, including intravenously, orally, intrathecally, topically to the eyes, skin or mucous membranes, in the form of ear or nasal drops, rectally or as part of a ex-vivo organ preservation solution.
- the cyclic DTC or TS derivative or mixture can also be administered directly to a blood vessel wall or within a lumen of a vessel, eg., during a catheter directed interventional procedure.
- an active compound or mixture as set forth herein can be administered directly to a vascular wall using perfusion balloon catheters, following or in lieu of coronary or other arterial angioplasty.
- 2-5 mL of a physiologically acceptable solution containing about 1 to 500 ⁇ M of the compound or mixture is administered at 1-5 atmospheres pressure to treat or prevent restenosis following angioplasty, followed by long-term administration using alternative routes as described above.
- Methods of the invention alternatively involve administration of a prescribing a dietary supplement containing a cyclic DTC or TS derivative, eg., in the form of total parenteral nutrition (TPN) and enteral feeds.
- TPN total parenteral nutrition
- DTC or TS derivatives can be administered in conjunction with other nutrients, such as Vitamin E, Co-enzyme Q10, Vitamin C, Vitamin A, Bioflavonoids, Ginseng, Grape skin extract, rutin, Zinc, Thiamin, biboflavin, niacinamide, pantothenic acid, pyridoxine, folic acid, biotin, cynacobalamin and other antioxidants.
- nutrients such as Vitamin E, Co-enzyme Q10, Vitamin C, Vitamin A, Bioflavonoids, Ginseng, Grape skin extract, rutin, Zinc, Thiamin, biboflavin, niacinamide, pantothenic acid, pyridoxine, folic acid, biotin, cynacobalamin and other antioxidants.
- a cyclic DTC or TS derivative in conjunction with other medications used in the treatment of inflammatory disease and related conditions, such as cardiovascular disease.
- Other medications useful in these combinatorial treatment methods include steroidal antiinflammatories, such as corticosteroids, and nonsteroidal antiinflammatories, for example aspirin, ibuprofen, indomethacin, fenoprofen, mefenamic acid, flufenamic acid, and sulindac.
- Additional adjunctive medicaments can include clotting inhibitors such as heparin; antithrombotic agents such as coumadin; calcium channel blockers such as varapamil, diltiazem, and nifedipine; angiotensin converting enzyme (ACE) inhibitors such as captopril and enalopril, and jS-blockers such as propanalol, terbutalol, and labetalol, among other combinatorially effective medicaments which will be apparent to the skilled practitioner.
- clotting inhibitors such as heparin
- antithrombotic agents such as coumadin
- calcium channel blockers such as varapamil, diltiazem, and nifedipine
- angiotensin converting enzyme (ACE) inhibitors such as captopril and enalopril
- jS-blockers such as propanalol, terbutalol, and labetalol, among other combinatorially effective medicaments which
- aqueous carriers may be used, e.g., water, buffered water, 0.4% saline, 0.3% glycine and the like. Many other suitable carriers are known in the art and readily formulated with the subject compounds, including biologically compatible gels and the like suitable for topical administration.
- the pharmaceutical compositions may be sterilized by conventional, well known sterilization techniques.
- the resulting formulations may be packaged for use or filtered under aseptic conditions and lyophilized, the lyophilized preparation being combined with a sterile aqueous solution prior to administration.
- Oral compositions for use within the invention will generally include an inert diluent or an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets.
- the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules.
- Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
- the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
- a binder such as microcrystalline cellulose, gum tragacanth or gelatin
- an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
- a lubricant such as magnesium stearate or sterotes
- a glidant such as colloidal silicon dioxide
- dosage unit forms can contain various other materials which modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or other enteric agents.
- the cyclic DTC or TS derivative (or pharmaceutically acceptable salt, complex, or derivative thereof) can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like.
- a syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
- Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include the following components : a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediarninetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
- the parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
- the active compound can also be administered through a dressing or transdermal patch.
- Methods for preparing transdermal patches are known to those skilled in the art . For example, see Brown, L., and Langer, R. , Transdermal Delivery of Drugs, Annual Review of Medicine, 39:221-229 (1988), incorporated herein by reference .
- the cyclic DTC or TS derivative is prepared with carriers that protect the compound against rapid elimination from the body, such as are routinely used in controlled release devices and formulations (eg. , implants and microencapsulated delivery systems) .
- Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides , polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
- Liposomal suspensions may also be pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811 (incorporated herein by reference) .
- liposome formulations may be prepared by dissolving appropriate lipid (s) (such as stearoyl phos- phatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container. An aqueous solution of the active compound is then introduced into the container. The container is swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.
- appropriate lipid such as stearoyl phos- phatidyl ethanolamine, stearoyl
- compositions for use within the invention may also contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH-adjusting and buffering agents, tonicity-adjusting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, etc.
- concentration of the cyclic DTC or TS derivative in these formulations can vary widely, i.e., from less than about 0.5%, usually at least about 1%, to as much as 15 or 20% by weight, and will be selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.
- humans, and other animals, in particular, mammals, suffering from in- flammatory conditions and diseases are treated by administering to the patient a pharmaceutical or therapeutic composition comprising an antiinflammatory effective amount of one or more cyclic DTC or TS derivatives, or a pharmaceutically acceptable salt, derivative, or complex thereof, in a pharmaceutically acceptable carrier or diluent.
- salts or complexes refers to salts or complexes that retain the desired biological activity of the cyclic, substituted DTC or TS derivative and exhibit minimal undesired toxicological effects.
- Nonlimiting examples of such salts are (a) acid addition salts formed with inorganic acids (for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like) , and salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, naphthalenedisulfonic acid, and polygalacturonic acid; (b) base addition salts formed with polyvalent metal cations such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel
- the active compound is included in the pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver to a patient an antiinflammatory effective amount without causing serious toxic effects in the patient treated.
- the active compound is preferably administered to achieve peak plasma concentrations of the compound of about 0.1 to 100 ⁇ M, preferably about l-10 ⁇ M.
- the concentration of active compound in the drug composition will depend on absorption, distribution, inactivation, and excretion rates of the drug, as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.
- the methods of the invention are shown to be useful for treating a wide variety of inflammatory conditions and diseases.
- the methods of the invention can be employed to treat ischemia-reperfusion injury, and for preventing or reducing related complications of cardiopulmonary bypass and extracorporeal membrane oxygenation (ECMO) .
- ECMO cardiopulmonary bypass and extracorporeal membrane oxygenation
- the methods provided herein are useful to prevent or alleviate systemic inflammatory induced shock or response syndrome associated with CPB, ECMO, shock, sepsis, severe pancreatitis and other injuries or disease states.
- Additional methods within the invention incorporate the foregoing treatments to prevent or reduce inflammatory conditions or diseases, including but not limited to, intimal hyperplasia; atherosclerosis; arthritis (osteo and rheumatoid) ; chronic inflammatory autoimmune diseases (eg., multiple sclerosis) ; inflammatory skin disease; periodontal disease; pulmonary injury (eg., ARDS, Asthma, COPD) ; GI inflammatory disorders (eg., inflammatory bowel disease, volvulus, ischemic gut, Crohn's disease);
- ischemic injury and/or rejection from transplantation eg., free tissue transfer and reimplantation of severed digits and extremities
- transplantation eg., free tissue transfer and reimplantation of severed digits and extremities
- ischemic injury from testicular or ovarian torsion e.g., hypoxic cerebrovascular injury, reocclusion after thrombolysis for acute myocardial infarction or thrombosis after microvascular reconstruction, stroke, vasospasm (eg., after aneurysm clipping, blumetals variant angina, CABG, or free tissue transfer for reconstructive surgery) .
- Yet additional methods within the invention incorporate the foregoing treatments to prevent or reduce conditions that are exacerbated, either primarily or secondarily, by inflammatory conditions, including infertility, the occurrence and size of heart attacks, cancer (malignant angiogenesis) , complications from diabetes (eg. , eye, kidney, neuropathy) , complications of chemotherapy, and complications of AIDS.
- cancer malignant angiogenesis
- diabetes eg. , eye, kidney, neuropathy
- the methods of the invention effectively inhibit (i.e., prevent or treat) oxidative stress-induced tissue injury in vivo, including injuries in the heart, brain, liver, kidneys, bone, immune system, skin, and other organs.
- the methods of the invention are useful to alleviate arrhythmia, lung injury, and other adverse sequelae caused by oxidative stress.
- These methods involve administration of an anti-oxidative stress effective amount of a cyclic DTC or TS derivative.
- Inhibition of oxidative stress is determined according to any of a variety of models and methods known in the art, for example based on well established in vi tro or in vivo protocols measuring cellular indices, physiological conditions, and other parameters indicative of the risk, or extent, of oxidative stress-related injury.
- the methods of the invention preferably achieve substantial inhibition of oxidative stress responses or injuries attributable thereto.
- administration of an anti-oxidative stress effective amount of a cyclic DTC or TS derivative in a clinical, ischemia/reperfusion (I/R) setting preferably results in at least a 10% reduction, more preferably a 20-30% and in some cases a 50-80% reduction of I/R related physiological responses or tissue injury compared to the relevant control value .
- Other preferred methods within the invention involve administration of a cyclic DTC or TS derivative, for example, ProDTC or PRoTDS, in an amount effective to prevent or treat systemic inflammatory response syndrome (SIRS) .
- SIRS systemic inflammatory response syndrome
- These and related methods involve administering, by local, regional, systemic or ex-vivo perfusion, to a tissue of the patient at risk or subject to inflammatory injury (eg., tissue subject to interval tissue ischemia) an anti-SIRS effective amount of the cyclic DTC or TS derivative to a mammalian patient.
- This treatment yields a measurable reduction, preferably a substantial reduction, in the risk or extent of the SIRS response .
- methods which employ a cyclic DTC or TS derivative that is contacted with cells or administered to a patient to specifically inhibit NF- ⁇ B activity. These methods result in detectable or substantial inhibition of one or more biological activities of NF-/.B, including but not limited to, NF-/.B nuclear translocation, release of an inhibitory subunit, I ⁇ B, of NF-/.B, NF- KB-mediated transcriptional activation, and/or NF-kB-mediated inflammatory responses.
- an anti-NF-/-B effective amount of a cyclic DTC or TS derivative is administered to yield detectable inhibition of NF-/.B nuclear translocation (see Examples, below) .
- Alternative methods yield detectable inhibition of the release of I ⁇ B, or of NF/cB- mediated transcriptional activation (see, eg., Schreck et al . , J. Exp . Med. 175:1181-1194, 1992, incorporated herein by reference) .
- NF- ⁇ B-mediated transcriptional regulation of selected genes, eg., tissue factor (TF) involved in specific inflammatory pathways or mechanisms is detectably or substantially inhibited.
- I/.Bo substantial degradation of I/.Bo; (see Examples below) .
- substantially degradation is meant that I/-Bat is not degraded by more than 50%, preferably by no more than 20-30%, and more preferably by no more than 5-10%, over control values in samples exposed to an anti-NF- ⁇ B effective amount of a DTC or TS derivative compared to controls.
- a cyclic DTC or TS derivative is administered to differentially inhibit NF-KB- mediated oxidative stress without affecting other inflammatory mechanisms and/or pathways that would detectably or substantially reduce desired responses, such as one or more of the beneficial responses elicited by TNF or LPS, thereby leaving the patient's ability to fight infection.
- desired responses such as one or more of the beneficial responses elicited by TNF or LPS
- specific methods are provided for inhibiting inflammatory responses without substantially elevating adverse inflammatory-stimulating chemokines (eg., IL-8, MCP-1, and GRO) .
- adverse inflammatory-stimulating chemokines eg., IL-8, MCP-1, and GRO
- a cyclic DTC or TS derivative is contacted with a cell or administered to a patient in an antiinflammatory effective amount which does not detectably or substantially yield an increase in an inflammatory-stimulating chemokine.
- preferred methods yield a maximal increase in inflammatory-stimulating chemokine levels (eg., as measured in plasma following IL-lc. or LPS stimulation) of less than 50% following administration of the cyclic DTC or TS derivative.
- the maximal increase is no more than 20-30%. More preferably, an increase of less than 10% follows administration of the antiinflammatory compound.
- administration of the compound attenuates levels of inflammatory-stimulating chemokines in the context of an ongoing inflammatory response (eg., in a patient experiencing sepsis or in a control sample stimulated by IL-1 or LPS) by 30- 50% or more.
- in vivo administration of the cyclic DTC and TS derivatives of the invention preferably yield a maximum level of IL-8 of 0.3 ng/ml, more preferably 0.25 ng/ml, and most preferably 0.1 ng/ml or lower.
- Preferred levels of GRO elicited or attenuated by the above methods are no greater than 4 ng/ml, preferably no greater than 3 ng/ml, and most preferably 1 ng/ml or less.
- preferred levels are less than 12 ng/ml, more preferably 8 ng/ml or less, and most preferably 5 ng/ml or less.
- a cyclic DTC or TS derivative alone or in a mixture, to preserve organs and tissues ex-vivo for purposes of transplantation or chemotherapy.
- the organ or tissue is contacted with an effective amount of the cyclic DTC or TS derivative, eg., in a perfusate, to reduce or prevent inflammatory injury normally associated with ex vivo tissue or organ maintenance.
- an organ being prepared for transportation and transplantation can be perfused, once, repeatedly, or continuously, with a preservation solution under normal or hypothermic conditions, to measurably reduce tissue damage expected under control (i.e., perfused without the effective compound or mixture) conditions.
- cyclic DTC or TS derivatives and pharmaceutical formulations administered within the methods of the invention must be physiologically acceptable.
- compounds and formulations with a therapeutic index of at least 2, preferably at least 5-10, more preferably greater than 10, are acceptable.
- the therapeutic index is defined as the EC 50 /IC 50 , wherein EC 50 is the concentration of compound that provides 50% inhibition of a target inflammatory response (eg.
- IC 50 is the concentration of compound that is toxic to 50% of target cells, eg., in an in vi tro toxicity assay.
- cellular toxicity can be measured by direct cell counts, trypan blue exclusion, or various metabolic activity studies such as 3 H-thymidine incorporation, as known to those skilled in the art.
- the methods set forth above reduce or prevent an acidotic response in a patient or sample so as to alleviate a principal toxic side effect associated with administration of DTC compounds other than the cyclic derivatives disclosed herein.
- preferred methods yield a maximal decrease in pH in in vivo applications to yield an arterial pH of about 7.1, preferably about 7.2, and more preferably about 7.3-7.45 or higher.
- a substantial response will vary at least 10% (above or below depending upon the parameter being measured) from the relevant control value. More preferably, the antiinflammatory response will vary 10-20%, sometimes 20-50%, and most preferably 50-100%, 100-200%, or more, compared to the relevant control value
- the methods of the invention provide substantial, unexpected advantages over prior methods which have used different DTCs, for example non-cyclic DTCs as exemplified by pyrrolidine-DTC (PDTC) , as potential agents to treat various conditions, including inflammation.
- preferred methods of treatment within the invention involve administration of a cyclic DTC or TS derivative, for example, ProDTC or PRoTDS, in an amount effective to selectively block specific inflammatory pathways or mechanisms, including specific NF- ⁇ B activities (eg., translocation without I-B degradation) and to selectively inhibit oxidative stress, while not significantly inhibiting other pathways or mechanisms, such as other pathways and mechanisms mediated by TNF and/or LPS- induced activation, and without eliciting other adverse sequelae, such as are attributable to deleterious cytokine induction.
- a cyclic DTC or TS derivative for example, ProDTC or PRoTDS
- Active compounds that are useful within the invention have been identified to include a discrete family of structurally and functionally related, cyclic derivatives of dithiocarbamates (DTCs) and thiuramsulfides (TSs) . These related compounds actively inhibit a range of inflammatory responses, particularly responses mediated by NF-KB activity and/or oxidative stress.
- DTCs dithiocarbamates
- TSs thiuramsulfides
- Operable DTC and TS derivatives within the invention are preferably synthesized using a cyclic, secondary amine, for example a cyclic, secondary amino acid such as proline or thioproline.
- a cyclic, secondary amine precursors for synthesis of cyclic derivatives of DTCs and TSs for use within the invention are provided in Figures 1A and IB .
- the precursors shown in Figure 1A are substituted, as discussed below, whereas the exemplary precursors shown in Figure IB need not be substituted to yield a preferred DTC or TS derivative.
- Cyclic DTCs useful within the invention preferably share the general formula R1,R2-N-C (S) S-R3 , wherein Rl and R2 constitute a cycle including the nitrogen atom of the dithiocarbamate.
- the ring may be 5-, 6-, or 7-membered, with a 4- to 6-membered bridge, and may contain either zero, one, or two double bonds .
- Members of this group of compounds preferably bear one or more, and preferably one or two substitutents in the bridge portion, eg., R4 and R5.
- the substituents may be selected from a variety of known substituents, eg., carboxyl, carboxylester, hydroxyl, nitro, amino or mercapto substitutents.
- Non-limiting examples of preferred substituents are shown in Figure 2.
- These and other substitutents may be combined (eg., by substitution at a CH 2 or N within the bridge) with a cyclic, secondary amine (eg., with any of the cyclic, secondary amines shown in Figures 1A and IB) to yield a preferred, cyclic, substituted secondary amine precursor for synthesis of DTC and TS derivatives useful within the invention.
- Non-limiting examples of cyclic, substituted secondary amines for synthesis of preferred DTC and TS derivatives within the invention are provided in Figures 3 and 4.
- R3 is a sodium, potassium, or free or substituted ammonium.
- Characteristic of preferred DTC derivatives for use within the invention is that they are more hydrophilic as compared to hydrophilicity of a parent compound lacking the above noted substituent (s) and/or heteroatom(s) and/or carbonyl function (s) and/or dehydrogenation features.
- the second group of compounds useful within the invention include cyclic thiruamsulfides, which can incorporate one or more sulfurs, eg., thiuramsulfides (TDs) , thiruramdisulfides (TDSs) , or thiuramtrisulfides (TTSs) .
- Preferred members of this group of compounds share the general formula R1,R2-N-C (S) -Sx-C(S) -N-R3 ,R4, wherein x is 1 to 8, and wherein Rl, R2 and R3 , R4 constitute independently a cycle including the nitrogen atoms of the respective dithiocarbamate residue. Accordingly, Rl, R2 may, or may not, form an identical bridge as R3 , R4. In certain aspects of the invention, bifunctional heterocycles are preferred.
- the ring(s) may be 5- to 7-membered, with a 4- to 6-membered bridge, and may contain either zero, one, or two double bonds.
- Preferred members of this group likewise bear one or more, and preferably one or two substitutents in the bridge portion (s), eg., R5 and R6.
- the substituents may be selected from carboxyl, carboxylester, hydroxyl, nitro, amino or mercapto substitutents.
- Non-limiting examples of cyclic, secondary amine precursors for synthesis of cyclic derivatives of TSs for use within the invention are provided in Figures 1A and IB .
- Non-limiting examples of preferred substituents are shown in Figure 2.
- Non-limiting examples of cyclic, substituted secondary amines for synthesis of preferred TS derivatives for use within the invention are provided in Figures 3 and 4.
- TS derivatives for use within the invention are more hydrophilic as compared to hydrophilicity of a parent compound lacking the above noted substituent (s) and/or heteroatom(s) and/or carbonyl function (s) and/or dehydrogenation features.
- Synthesis of cyclic DTC derivatives for use within the invention preferably involves reaction of a cyclic, secondary amine, preferably a cyclic, substituted, secondary amine, with carbon disulfide (CS 2 ) in alkaline, ethanolic solution (see, eg., Frank et al . , Carcinogenesis 11:199-203, 1990, incorporated herein by reference) .
- CS 2 carbon disulfide
- Other modifications eg., to provide alternate or additional features including substituent (s) , heteroatom(s) , carbonyl function(s), and/or dehydrogenation, are provided in accordance with conventional methods and will depend on starting materials (eg., structure of the secondary amine precursor) , desired end products, and other factors understood by the artisan.
- the synthetic reaction can utilize a variety of bases and salts.
- the reaction may yield an ammonium salt of a dithiocarbamic acid.
- Figure 5 depicts an exemplary synthetic reaction (and putative reaction mechanism) of CS 2 and L-proline in ethanol and NH 3 to yield a salt of a preferred DTC derivative, prolinedithiocarbamate (ProDTC) for use within the invention.
- ProDTC prolinedithiocarbamate
- Figure 6 illustrates other, non-limiting examples of reactions yielding preferred DTC derivatives for use within the methods of the invention.
- the Figure illustrates an exemplary reaction of piperidine-4-carbonic acid with CS2 to yield N,N- (3-carboxy-pentamethylene) dithiocarbamate, and exemplary synthesis of a multiply substituted DTC derivative, N,N- (l-carboxy-3-hydroxy) -tetramethylene-dithiocarbamate, from 4-hydroxy-trans-proline.
- Preparation of cyclic, substituted TS derivatives for use within the invention involves oxidation of a corresponding DTC compound using an appropriate oxidan (see, eg., Kitson, Biochem J. 155:445-448, 1976, incorporated herein by reference) .
- an appropriate oxidan see, eg., Kitson, Biochem J. 155:445-448, 1976, incorporated herein by reference
- Pro-TDC-sodium salt may be oxidized with iodine/potassium iodide to yield a preferred TS derivative, prolinethiuramdisulfide (Pro-TDS) , for use within the invention.
- a more preferred oxidan is nitrogendioxid (N 2 0 4 ) which renders excess reactants volatile and saves a clean up step.
- synthesis of TS derivatives for use within the invention can utilize a variety of conventional modifications, eg., to provide alternate or additional features including substituent (s) , heteroatom(s) , carbonyl function(s), and/or dehydrogenation, depending on starting materials, desired end products, and other factors.
- substituent (s) e.g., to provide alternate or additional features including substituent (s) , heteroatom(s) , carbonyl function(s), and/or dehydrogenation, depending on starting materials, desired end products, and other factors.
- alternative bases, salts, and reaction conditions can be used in accordance with ordinary chemical practice.
- cytokine-mediated shock remains a significant contributor to morbidity and mortality among hospitalized patients.
- Cytokine-induced shock is characterized clinically by a reduction in mean arterial pressure (MAP) , an increase in heart rate, an increase in cardiac output, and a marked reduction in systemic vascular resistance. The result is an inability to adequately perfuse end organ tissue and the development of multiple system organ failure and death.
- MAP mean arterial pressure
- IL-1 is a principle component of the systemic inflammatory response syndrome (SIRS) .
- SIRS systemic inflammatory response syndrome
- IL-1 synthesis occurs early in the inflammatory response and thus has a proximal role in the induction of other proinflammatory cytokines.
- IL-1 production has been directly linked to the development of hypotension, shock, multi -organ failure, hematologic dyscrasia, and death in experimental models and patients with SIRS.
- the pathophysiology of cytokine-induced shock is thought to be mediated by inducible changes at the microvascular level that occur when the endothelium is exposed to circulating cytokines.
- Quiescent endothelial cells lining the microvasculature respond to inflammatory stimuli and cell injury by activating signal transduction pathways that transmit signals through the cytoplasm to the nucleus. These signals result in the transcription, translation, and expression of several genes involved in SIRS.
- IL-1 proinflammatory, procoagulant, and vasoactive genes activated in this process
- VCAM vascular cell adhesion molecule
- IAM intercellular adhesion molecule
- IL-8 interleukin-8
- monocyte chemotactic protein-1 monocyte chemotactic protein-1
- iNOS inducible nitric oxide synthase
- tissue factor tissue factor
- NF-/.B is a ubiquitous, inducible, fast-responding transcription factor that exists in an inactive form in the cell cytoplasm.
- NF-/.B is translocated to the nucleus where the now activated NF-KB binds to specific nucleotide sequences in the promoter region of these genes and, in association with other transcription factors, initiates gene expression (reviewed in Baeuerle et al., Ann. Rev. Immunol. 12:141-79. 1994, incorporated herein by reference) .
- These DNA binding proteins are thought to facilitate the assembly of higher order complexes of transcriptional activators that interact as a unit with the basal transcriptional machinery needed to initiate transcription.
- NF-/.B is activated in vivo at sites of inflammation in response to bacterial lipopolysaccharide (LPS) , and this activation temporally precedes the expression of E-selectin, ICAM, and VCAM at these sites. This suggests a role for NF-KB in the activation of these genes in vivo during severe systemic inflammation. It is unknown, however, if inhibiting NF-/.B will prevent the shock-like state that is associated with SIRS.
- LPS bacterial lipopolysaccharide
- dithiocarbamates, and cyclic, dithiocarbamate derivatives represented by the exemplary group members PDTC, and ProDTC, that reportedly or demonstrably inhibit NF-KB, to attenuate IL-1-induced shock in vivo is demonstrated.
- the rabbits were anesthetized with an initial intramuscular injection of ketamine (35 mg/kg) and xylazine (5 mg/kg) . They were intubated using an endotracheal tube (inner diameter 3.0 mm) and maintained on inhaled Halothane anesthesia (1%) in 1010% oxygen with a tidal volume of 15 cc/kg for the duration of the study using a small animal ventilator.
- Minute ventilation was adjusted according to arterial blood gas measurements to maintain arterial pH between 7.45 and 7.50 while keeping carbon dioxide tension between 25 and 35 mm Hg.
- Body temperature was maintained at 36° to 38° C with a heating pad.
- a 20-gauge flexible catheter was placed in the left common carotid artery to continuously measure heart rate (HR) , mean arterial pressure (MAP), and collect blood samples.
- HR heart rate
- MAP mean arterial pressure
- a double lumen thermodilution probe and injectate catheter (Model 94-011-3F, Baxter Healthcare Corporation, Irvine, CA) were placed through the left femoral artery and vein in order to measure core temperature and cardiac output (CO) by thermodilution.
- Blood samples (0.5-1.0 ml) were taken from the carotid catheter 60 minutes before IL-lo or saline administration, and at time 0, and 30, 60, 120, 180, and 240 minutes after saline or IL-lo; administration, and the volume of blood taken was replaced by an equal volume of saline .
- the MAP remained decreased by approximately 19% from 120-240 minutes but this drop was no longer significant compared to time 0 pressures after 120 minutes.
- the MAP observed in Group 2 after IL-1 injection was significantly lower at every time point throughout the entire study period (P ⁇ 0.05) .
- the change in the MAP of rabbits in Group 1 was not significant from time 0 at any time point.
- Rabbits in Group 2 experienced a drop in SVR that was significantly below the SVR measured in Group 3 and Group 4 at 30 and 60 minutes after IL-1 infusion (P ⁇ 0.05).
- the SVR of Group 2 continued to be significantly lower than that of the saline control animals in Group 1 for the duration of the experimental time period (P ⁇ 0.05).
- the SVR calculated in Group 3 was significantly elevated above that calculated in Group 2 at 120 and 180 minutes (P ⁇ 0.05).
- Animals in Group 3 and Group 4 exhibited a transient, significant increase in CO during the first 60 and 120 minutes respectively following IL-1 treatment with return to baseline values after 120 minutes ( Figure 11) . CO measured in these groups was not significantly different from that of the saline controls in Group 1 at any time point.
- Rabbits in Group 2 experienced a dramatic rise in CO by 120 minutes that was significantly elevated above that measured in Group 1 after 120 minutes (P ⁇ 0.05).
- the present example compares metabolic acidosis effects caused by in vivo administration of a dithocarbamate and a cyclic, dithocarbamate derivative, represented by the exemplary group members PDTC and ProDTC, respectively to alleviate interleukin 1 (IL-1) -induced hemodynamic instability.
- a dithocarbamate and a cyclic, dithocarbamate derivative represented by the exemplary group members PDTC and ProDTC, respectively to alleviate interleukin 1 (IL-1) -induced hemodynamic instability.
- rabbits were housed, anesthetized, maintained, and catheterized to measure core temperature and cardiac output (CO) as described above. Blood samples were removed and hemodynamic parameters and arterial blood gases were also recorded as above .
- CO cardiac output
- the blood gas profile of the ProDTC treated animals was unchanged from that of saline control animals one hour after receiving the ProDTC. Animals treated with saline or ProDTC did not experience significant acidosis until after receiving IL-1, suggesting that the cytokine was primarily responsible for the moderate acidosis observed in this sample group . ProDTC treatment did not immediately alter the cytokine-induced acidosis, as the acid-base status of the IL-1 control group and the ProDTC treated animals was almost identical up to 180 minutes after IL-1 infusion. Animals treated with ProDTC, however, experienced an increase in arterial pH after this point and no longer exhibited significant acidemia compared to saline control animals by the end of the experimental protocol . These changes cannot be attributed to differences in ventilation, as the ventilatory settings were not altered after similar and stable baseline blood gas measurements were attained in each group.
- Inflammation is characterized by the accumulation of neutrophils and monocytes in tissue. Monocytic and endothelial cells orchestrate this response to injury in part by secreting chemotaxins that recruit neutrophils and monocytes into tissue.
- IL-8, GRO, and MCP-1 are members of the chemokine family of proteins that are potent neutrophil and mononuclear cell chemoattractants and activators . Johnson et al . , J. Biol. Chem. 271 (18) : 10853-10858 , 1996; Kajikawa et al . , J. Immunol . Meth. 197:19-29, 1996, each incorporated herein by reference.
- these chemokines have many other biological activities including regulatory effects on melanoma growth, fibroblast collagen production, activation of and adhesion to endothelial cells, myelopoiesis, and angiogenesis . Johnson et al . , J. Biol. Chem. 271(18) :10853-10858, 1996, incorporated herein by reference.
- the present example compares the effects on chemokine levels caused by in vivo administration of a dithocarbamate and a cyclic, dithocarbamate derivative, represented by the exemplary group members PDTC and ProDTC, respectively.
- rabbits were housed, anesthetized, maintained, and catheterized to measure core temperature and cardiac output (CO) as described above. Blood samples were removed and hemodynamic parameters and arterial blood gases were recorded as above . Bioassays of chemokines from 1.0 ml samples of citrated plasma were conducted as previously described. Kajikawa et al., J. Immunol . Meth. 197:19-29, 1996; Johnson et al . , J. Biol. Chem. 271:10853-10858, 1996, each incorporated herein by reference.
- Sandwich enzyme-linked immunosorbent assays were constructed using goat polyclonal anti-recombinant rabbit IL-8, MCP-1, or GRO IgG as the both the capturing and detecting antibody.
- Anti-recombinant rabbit IL-8 and MCP-1 antibody was diluted to 200 mg/mL with 0.1 M bicarbonate buffer pH 9.6 and anti-recombinant rabbit GRO antibody was diluted 1:350 in the same buffer.
- Polystyrene 96-well plastic plates (Coster, Cambridge, MA) were coated with antibody solutions and incubated overnight at 4°C. The plates were rinsed twice with Dulbecco's PBS and blocked with 110% non-fat milk for 1 h at 37°C.
- the reaction was stopped with 100 mL/well 1.0 M phosphoric acid and the optical density (450 nm) in each well was measured using a microtiter plate reader (Dynatech Co.,
- Cytokine concentration in the plasma samples was determined based on standard curves generated.
- MCP-1 plasma levels peaked 120 minutes after IL-la infusion (17.77 ⁇ 3.11 ng/mL) and remained significantly elevated for the duration of the study period. MCP-1 plasma levels were not altered in response to IL-la in the PDTC treated group as the level of MCP-1 detected after 120 minutes was significantly elevated at 24.8 ⁇ 4.03 ng/mL and remained significantly elevated for the entire study (P ⁇ 0.05).
- the MCP-1 levels measured in the ProDTC treated group were not significantly different from those measured in the saline control group at any time point.
- IL-la induced a rapid increase in the GRO chemokine which peaked at 60 minutes in the untreated group.
- GRO levels rose unabated in the PDTC treated group ( Figures 16-18) .
- Plasma levels of GRO were significantly elevated after IL-la in the untreated and PDTC treated group at every time point compared to the saline control group (P ⁇ 0.05).
- the plasma level of GRO measured in the PDTC treated group was significantly higher than that measured in the ProDTC group at 60, 120, and 180 minutes after IL-la injection (P ⁇ 0.05) .
- the plasma level of GRO in the ProDTC treated animals was not significantly different from that measured in the saline controls after 180 minutes ( Figures 16-18) .
- PDTC has been reported to inhibit IL-1-induced NF-/.B nuclear binding activity necessary for expression of the chemokines (IL-8, MCP-1, GRO) in vi tro (see, eg., Mukaida et al . , J. Immunol. 143 (4) : 1366-71 , 1989; Siebenlist et al . , Ann. Rev. Cell Biol. 10:405-455, 1994, each incorporated herein by reference) , PDTC treatment actually increases the levels of these chemokines beyond levels seen in rabbits receiving only IL-1. In contrast, ProDTC treatment decreases chemokine expression in response to IL-1.
- the mechanism underlying the adverse stimulation of chemokines in the presence of PDTC may relate to the severe acidosis induced by this compound. This response triggered by PDTC may overwhelm the reported effects of this compound of inhibiting NF-KB, thereby promoting a net deleterious response to IL-1. In contrast, ProDTC, which does not induce acidosis at comparable dosage with PDTC, effectively prohibits the chemokine response to IL-1.
- PDTC is expected to be less effective in preventing cellular activation because it does not block NF- ⁇ B as completely and effectively as ProDTC.
- Our experiments indicate that ProDTC reliably and effectively blocks NF-/.B.
- the evidence herein indicates that PDTC has little or no effect on the inhibition of chemokine levels in response to cytokines, and that it may in fact exacerbate this deleterious response.
- ProDTC on the other hand, effectively prevents the cytokine induced increase in plasma chemokines (IL-8, GRO, and MCP-1) . This provides further evidence that PDTC acts via an alternative pathway or mechanism compared to ProDTC, or that ProDTC acts via pathways or mechanisms in addition to those it might share with PDTC.
- ProDTC and other cyclic DTC derivatives disclosed herein is thought to enable stereotypic inhibition of the IL-1 receptor complex or additional mediators or cytokine receptors induced by IL-1 at the cell surface.
- inflammatory response to injury should be more effectively attenuated by ProDTC and other cyclic DTC derivatives compared to non-cyclic DTCs, as the present data demonstrate.
- ProDTC may block one of the several kinases or signalling proteins involved in the MAPK or SAPK pathways of activation that have been implicated in chemokine induction.
- NF-kB is not a sole regulator of cytokine-mediated gene expression in vivo involved in oxidative stress-induced inflammatory events.
- ProDTC may exhibit its effects on a transcription factor that is inaccessible or unaffected by PDTC.
- ProDTC Superior chelating properties of ProDTC may thus account for the ability of this compound to effectively prevent inflammatory responses, such as the chemokine response, that are mediated in part by intracellular transition metals acting in signalling, or as cofactors, for particular enzymes such as superoxide dismutase. Further, it is possible that ProDTC, unlike PDTC, may inhibit transcription events mediated by zinc fingers. Additionally, PDTC has been shown to chelate extracellular metals, such as copper, and carry them across the cell membrane. Orrenius et al . , Biochem. Soc . Trans. 24:1032-1038, 1996, incorporated herein by reference.
- ProDTC and other cyclic DTC derivatives disclosed herein are more stable in vivo, and thus less likely than PDTC and other DTCs to cause an increase in free metal ions .
- ProDTC may have an affect on translation that is absent with PDTC.
- ProDTC and its related derivatives exhibit greater stability and bioavailabilty than PDTC, which likely improves delivery of the drug and may account in part for its ability to inhibit chemokine responses, in addition to their other, superior anti-inflammatory effects.
- HUVEC human umbilical vein endothelial cells
- hypoxia reoxygenation after hypoxia
- H 2 0 2 reactive oxygen intermediate
- HUVEC were also treated with a specific tyrosine phosphatase inhibitor, pervanadate, to examine tyrosine phosphorylation of IkB in oxidative stress-mediated NF- ⁇ B activation.
- Human umbilical vein endothelial cells were obtained by collagenase (Worthington Biochemical, Freehold, NJ) digestion. Cultures were maintained in RPMI 1640 (Whittaker, Walkerville, MD) supplemented with 10% adult bovine serum (JRH Biosciences, Lenexa, KS) , heparin (90 units/mL; Sigma, St. Louis, MO) , endothelial cell growth supplement (50 units/mL; Collaborative Research, Bedford, MA) and antibiotics in room air at 37°C.
- HUVEC were serially passaged by brief exposure to Versene (GIBCO/BRL, Grand Island, NY) and 0.05% Trypsin with EDTA (GIBCO/BRL, Grand Island, NY) . Third passage confluent HUVEC monolayers were used in all experiments . Hypoxia and Reoxygenation
- Normoxic control cells were maintained in a standard incubator at room air oxygen tension (21% oxygen) at 37°C designated "normoxia" .
- To expose HUVECs to hypoxia cultures were placed in a controlled environmental chamber (Coy Laboratory Products, Ann Arbor, MI) at 37°C and maintained at oxygen tension of 2-3% oxygen. Oxygen content in the media over the HUVECs equilibrated with the hypoxic environment of the chamber within 10 minutes as measured by a Clark electrode (data not shown) .
- To expose HUVECs to hypoxia and reoxygenation cultures were removed from the hypoxia chamber and placed in the normoxic incubator for designated periods of time.
- Binding reactions occurred at room temperature for 20 minutes. Proteins were resolved on a 6% nondenaturing polyacrylamide gel at 100 V for 1-2 hours in a 0.5% TBE buffered solution. The gels were dried and blotted overnight, and autoradiographed.
- TNF-c induced rapid degradation of IKBQ; protein, with concomitant nuclear translocation of NF- ⁇ B within 5-10 minutes.
- Complete IKBC. degradation was observed after 15 minutes, with restoration of I ⁇ B ⁇ by 1 hr during continuous exposure to TNF-o;. Similar results were obtained when cells were treated with IL-1/3 or LPS.
- HUVEC cultures that were exposed to 2 hours of hypoxia followed by reoxygenation demonstrated rapid nuclear translocation of NF- ⁇ B within 15 minutes, similar to that observed when HUVEC were treated with TNF- ⁇ ( Figure 19) .
- Rapid nuclear translocation of NF- ⁇ B also occurred in HUVECs exposed to hypoxia alone, or treated with H 2 0 2 ( Figures 19 and 20) .
- reoxygenation of hypoxic HUVEC did not result in degradation of IKBCU ( Figure 19) .
- exposure of HUVEC to hypoxia, or treatment of HUVEC with H 2 0 2 induced a similar pattern of NF- ⁇ B nuclear translocation without I B ⁇ degradation ( Figures 19 and 20) .
- Pervanadate consists of H 2 0 2 and vanadate, a tyrosine phosphatase inhibitor. Pervanadate thus preserves transient tyrosine phosphorylation of proteins and potentiates signal transduction pathways activated by H 2 0 2 (or other ROIs) . Moreover, tyrosine phosphorylation of IKBC. in cells treated with pervanadate is reported to block IKBC. degradation. As shown in Figure 20 pervanadate treatment initiated rapid and pronounced nuclear translocation of NF- ⁇ B without associated degradation of I BO;. Neither IKBC. nor I Be underwent degradation in HUVEC exposed to oxidative stress.
- IkB can be phosphorylated on a tyrosine residue at position 42 of I ⁇ B, in close proximity to the two serine phosphoacceptor sites . Tyrosine phosphorylated IKB is protected from TNF-induced degradation, although the mechanism of this protective effect is not known.
- oxidative stress activates a signaling pathway resulting in tyrosine phosphorylation of IKBO, rather than serine phosphorylation induced by TNF.
- Tyrosine phosphorylation causes IKBO; to dissociate from NF- ⁇ B but, unlike serine phosporylation, does not signal IKBO; degradation.
- oxidative stress activates the proinflammatory transcription factor NF- ⁇ B through an alternative pathway or mechanism from previously described pathways. This discovery allows targeting and blockade of the proinflammatory transcriptional response to oxidative stress (eg., as occurs in I/R), while leaving the endothelial cell's ability to respond to infection, or to beneficial cytokine signals, intact.
- Non-cyclic DTCs as exemplified by PDTC, are reported in the literature to inhibit TNF-induced NF- ⁇ B activation. Satriano et al . , J. Clin. Invest. 94 (4) :1629-36, 1994, incorporated herein by reference. This report, combined with the data herein, further indicates that the cyclic DTC and TS derivatives used within the present invention, exemplified by Pro-DTC, selectively inhibits an oxidant pathway for NF- ⁇ B activation.
- the selectivity of ProDTC and its related compounds for inhibiting an oxidant pathway involved in NF- ⁇ B activation may be due to a specific affinity that these compounds have for the kinase that tyrosine phosphorylates NF- ⁇ B under oxidative stress. Because oxidative stress and infectious stimuli (eg., TNF and LPS) appear to signal NF- ⁇ B activation through different pathways, and because the cyclic DTC and TS derivatives described herein selectively inhibit this pathway, these compounds allow specific blockade of ischemia-reperfusion or oxidative injury, without effecting the host's ability to respond to infectious stimuli.
- This discovery provides a major advantage over currently available techniques to prevent microvascular activation, such as the use of monoclonal antibodies to prevent neutrophil adhesion, which are known to greatly increase the host risk of infection.
- Ischemia-reperfusion (I/R) injury exists as a continuum ranging from mild stunning, characterized by reversible post-ischemic organ dysfunction, to infarction, which is characterized by irreversible myocellular necrosis and programmed cell death (apoptosis) .
- Boyle et al. Ann. Thorac. Surg. 62 (6) :1868-75, 1996; Lefer et al . , Ann. Rev. Pharmacol. Toxicol. 33:71-90, 1993, each incorporated herein by reference.
- reperfusion of ischemic myocardium can lead to severe cardiogenic shock, with resulting multiorgan dysfunction, and even death.
- LVPSP left ventricular peak systolic pressure
- LEDP left ventricular end diastolic pressure
- a 4.0 Vicryl suture was passed twice around a large arteriolateral branch of the left main coronary artery supplying the majority of the left ventricle, and the ends of the suture passed through a small length of polyethene tubing to form a snare . After a 20-30 minute stabilization period, baseline values were recorded.
- Group I Six animals, referred to as group I, were given 1 cc of PBS 15 minutes prior to the I/R protocol.
- the coronary artery was reoccluded, and 6 mL of 10% Evan's Blue dye (Sigma, Saint Louis, MO) was injected into the left atrium and allowed to circulate and stain all perfused tissue.
- the area supplied by the ligated vessel remained unstained, demarcating the myocardium at risk for infarction.
- the left ventricle was isolated from the rest of the heart, weighted, and then cut into 2 mm-thick transverse slices. The normal myocardium, which stained blue, was separated from the area at risk, which was unstained.
- the area at risk was placed in a 37°C solution of 1% triphenyl- tetrazolium chloride (TTC) for 30 minutes. TTC stains the viable tissue brick red and leaves the necrotic zone pale. The TTC-red (non-infarcted) tissue was separated from the TTC-pale (necrotic) tissue and each area was weighed. The left ventricular area at risk (LVAAR) was calculated as the sum of the noninfarcted and necrotic tissue weight of the tissue perfused by the occluded vessel divided by the weight of the left ventricle, expressed as a percent.
- TTC triphenyl- tetrazolium chloride
- the left ventricular area of necrosis was calculated as the weight of necrotic tissue divided by the weight of the left ventricle, expressed as a percent.
- the infarct size was calculated by dividing the weight of the TTC-pale tissue by the weight of the total area at risk (LVA ⁇ /LVAAR) .
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU47220/99A AU4722099A (en) | 1998-06-26 | 1999-06-24 | Inhibition of NF-kappaB mediated tissue injury using dithiocarbamate derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10597698A | 1998-06-26 | 1998-06-26 | |
US09/105,976 | 1998-06-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000000192A1 WO2000000192A1 (en) | 2000-01-06 |
WO2000000192A9 true WO2000000192A9 (en) | 2000-09-21 |
Family
ID=22308801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/014490 WO2000000192A1 (en) | 1998-06-26 | 1999-06-24 | INHIBITION OF NF-λB MEDIATED TISSUE INJURY USING DITHIOCARBAMATE DERIVATIVES |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU4722099A (en) |
WO (1) | WO2000000192A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003531138A (en) | 2000-03-21 | 2003-10-21 | アセロジエニクス・インコーポレイテツド | N-substituted dithiocarbamates for the treatment of biological diseases |
AU2001261409A1 (en) * | 2000-05-11 | 2001-11-20 | Oklahoma Medical Research Foundation | Prevention of insulin-dependent diabetes, complications thereof, or allograft rejection by inhibition of cyclooxygenase-2 activity with NS398 or PDTC |
CN116421594A (en) * | 2022-01-04 | 2023-07-14 | 中南大学 | NLRP3 inflammatory corpuscle inhibitor and application thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5783596A (en) * | 1992-10-30 | 1998-07-21 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
US5380747A (en) * | 1992-10-30 | 1995-01-10 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
-
1999
- 1999-06-24 WO PCT/US1999/014490 patent/WO2000000192A1/en active Application Filing
- 1999-06-24 AU AU47220/99A patent/AU4722099A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2000000192A1 (en) | 2000-01-06 |
AU4722099A (en) | 2000-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU692426B2 (en) | Dithiocarbamates for the treatment of atherosclerosis and other cardiovascular and inflammatory diseases | |
US10195204B2 (en) | Methods of treating hemoglobinopathies | |
KR101939401B1 (en) | Composition for preventing or treating ischemic cardiac diseases comprising inhibiting agent for synthesis or secretion of AGE-albumin of mononuclear phagocyte as active ingredient | |
EP2374456B1 (en) | Edoxaban dosage regime | |
Sieber et al. | In vivo angiogenesis in normal and portal hypertensive rats: role of basic fibroblast growth factor and nitric oxide | |
CA2139851A1 (en) | Method of treating hyperproliferative vascular disease | |
Li et al. | Quercetin attenuates trauma-induced heterotopic ossification by tuning immune cell infiltration and related inflammatory insult | |
MXPA03010493A (en) | Use of sulodexide for the treatment of inflammatory bowel disease. | |
Yeh et al. | Cardiomyocytic apoptosis limited by bradykinin via restoration of nitric oxide after cardioplegic arrest | |
US6187822B1 (en) | Wound treatment through inhibition of adenosine diphosphate ribosyl transferase | |
KANG et al. | In vitro evaluation of antiproliferative potential of calcium channel blockers in human Tenon's fibroblasts | |
JP2010518154A (en) | TGF-beta stimulating factor and additional agents that reduce side effects | |
US6150401A (en) | Use of MEK1 inhibitors as protective agents against damage due to ischemia | |
WO2000000192A9 (en) | INHIBITION OF NF-λB MEDIATED TISSUE INJURY USING DITHIOCARBAMATE DERIVATIVES | |
CA3137138A1 (en) | Methods of treating hypertension with activators of tie-2 | |
EP1085859A1 (en) | Wound treatment through inhibition of adenosine diphosphate ribosyl transferase | |
CA3234847A1 (en) | New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases | |
US6319955B1 (en) | Use of MEK1 inhibitors as protective agents against damage due to ischemia | |
US20040101902A1 (en) | Inhibition of Egr-1 expression by ppar-gamma agonists and related compositions and methods | |
US20070197599A1 (en) | Hydroxylamines and derivatives as anti-angiogenic agents | |
KR20220041847A (en) | Compounds and methods for treating fibrotic pathology | |
US20210161900A1 (en) | Compositions and methods for the treatment of senescent tumor cells | |
Sun et al. | Depression of the inotropic action of isoprenaline by nitric oxide synthase induction in rat isolated hearts | |
Murthy et al. | Recent developments in inflammatory bowel disease therapy | |
US20060116403A1 (en) | Therapeutic target and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/21-21/21, DRAWINGS, REPLACED BY NEW PAGES 1/13-13/13; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |